Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11

Cellular Immunology

Volumn 270, Issue 1, 2011, Pages 62-69

  Matijevic, Mark ^a   Hedley, Mary Lynne ^a   Urban, Robert G ^a   Chicz, Roman M ^a   Lajoie, Christa ^a   Luby, Thomas M ^a  

^a EISAI INC   (United States)

Author keywords

Amolimogene; Cervical dysplasia; Cross reactive T cells; ELISpot; Human papillomavirus; Immunotherapy; Plasmid DNA; Poly (lactide co glycolide) microparticles

Indexed keywords

AMOLIMOGENE BEPIPLASMID; EPITOPE; HLA A2 ANTIGEN; PLACEBO; POLYGLACTIN; PROTEIN E6; PROTEIN E7;

ANTIGENICITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IN VITRO STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA;

ADULT; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNIZATION; IMMUNODOMINANT EPITOPES; PLASMIDS; POLYGLACTIN 910; PRECURSOR CELLS, T-LYMPHOID; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79959840034     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.04.005     Document Type: Article

References (43)

1. Duggan-Keen M.F., Brown M.D., Stacey S.N., Stern P.L. Papillomavirus vaccines. Front. Biosci. 1989, 3:1192-1208.
2. Kaufman R.H., Adam E., Vonka V. Human papillomavirus infection and cervical carcinoma. Clin. Obstet. Gynecol. 2000, 43(2):363-380.
3. Howley P.M. Role of human papillomaviruses in human cancer. Cancer Res. 1991, 51:5019-5022.
4. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 2008, 109(Suppl. 2):S15-S21.
5. Wheeler C.M. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet. Gynecol. Clin. North Am. 2008, 35(4):519-536.
6. Oaknin A., Barretina M.P. Human papillomavirus vaccine and cervical cancer prevention. Clin. Transl. Oncol. 2008, 10(12):804-811.
7. Bozanovic T., Ljubic A., Momcilov P., Milicevic S., Mostic T., Atanackovic J. Cold-knife conization versus the loop electrosurgical excision procedure for treatment of cervical dysplasia. Eur. J. Gynaecol. Oncol. 2008, 29(1):83-85.
8. Stern P.L., Brown M., Stacey S.N., Kitchener H.C., Hampson I., Abdel-Hady E.S., Moore J.V. National HPV immunity and vaccination strategies. J. Clin. Virol. 2000, 19(1-2):57-66.
9. Hebner C.M., Laimins L.A. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol. 2006, 16(2):83-97.
10. Subramanya D., Grivas P.D. HPV and cervical cancer: updates on an established relationship. Postgrad. Med. 2008, 120(4):7-13.
11. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
12. Dyson N., Howley P.M., Munger K., Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
13. Von Krough Geo. Management of anogenital warts (condylomata acuminate). Eur. J. Dermatol. 2001, 11:598-603.
14. Lima K.M., Rodrigues J.M. Poly-dl-lactide-co-glycolide microspheres as a controlled release antigen delivery system. Braz. J. Med. Biol. Res. 1999, 32(2):171-180.
15. Hedley M.L. Formulations containing poly (lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opin. Biol. Ther. 2003, 3(6):903-910.
16. Hedley M.L., Barman S.P. Microparticle delivery of plasmid DNA to mammalian cells. Methods Mol. Biol. 2003, 245:265-286.
17. O'Hagan D.T., Singh M., Ulmer J.B. Microparticles for the delivery of DNA vaccines. Immunol. Rev. 2004, 199:191-200.
18. Prior S., Gander B., Blarer N., Merkle H.P., Subira Merkle M.L., Irache J.M., Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 2002, 15:197-207.
19. Garcia F., Petry K.U., Muderspach L., Gold M.A., Braly P., Crum C.P., Magill M., Silverman M., Urban R.G., Hedley M.L., Beach K.J. Amolimogene for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 2004, 103(2):317-326.
20. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the IFN-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods 1997, 210:167-174.
21. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 2001, 7:1127-1135.
22. Pass H.A., Schwarz S.L., Wunderlich J.R., Rosenberg S.A. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 1998, 4:316-323.
23. Mwau M., McMichael A.J., Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retroviruses 2002, 18:611-618.
24. Matijevic M., Urban R.G. Use of Interferon-γ ELISPOT in Monitoring Immune Responses in Humans. Handbook of ELISPOT, Methods in Molecular Biology 2005, vol. 302:237-251. Humana Press.
25. Crum C.P., Beach K.J., Hedley M.L., Yuan L., Lee K.R., Wright T.C., Urban R.G. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. J. Infect. Dis. 2004, 189(8):1348-1354.
26. Manos M., Lee K., Greer C., Waldman J., Kiviat N., Holmes K., Wheeler C. Looking for human papillomavirus type 16 by PCR. Lancet 1990, 335(8691):734.
27. Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384:134-141.
28. Currier J.R., Kuta E.G., Turk E., Earhart L.B., Loomis-Price L., Janetzki S., Ferrari G., Birx D.L., Cox J.H. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 2002, 260 1-2:157-172.
29. Anderson K., Cresswell P., Gammon M., Hermes J., Williamson A., Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted, cell mediated lysis. J. Exp. Med. 1991, 174:489-492.
30. M.L. Hedley, R.G. Urban, R.M. Chicz, US 2005/0100928 A1, 2005.
31. Klencke B., Matijevic M., Urban R.C., Lathey J.L., Hedley M.L., Berry M., Thatcher J., Weinberg V., Wilison J., Darragh T., Jay N., DaCosta M., Palefsky J.M. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin. Cancer Res. 2002, 8:1028-1037.
32. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., Kast W.M., Fascio G., Marty G., Marty V., Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 2000, 6:3406-3416.
33. Nimako M., Fiander A.N., Wilkinson G.W., Borysiewicz L.K., Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia garde III. Cancer Res. 1997, 57(21):4855-4861.
34. Molling J.W., De Gruijl T.D., Glim J., Moreno M., Rozendaal L., Meijer C.J.L.M., Van den Eertwegh A.J.M., Scheper R.J., Von Blomberg M.E., Bontkes H.J. CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int. J. Cancer 2007, 121:1749-1755.
35. Adurthi S., Krishna S., Mukherjee G., Bafna U.D., Devi U., Jayshree R.S. Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. Am. J. Rep. Imm. 2008, 60:55-65.
36. Chiarella P., Massi E., DeRobertis M., Fazio V.M., Signori E. Strategies for effective naked-DNA vaccination against infectious diseases. Recent Patents Anti-Infect. Drug Disc. 2008, 3(2):93-101.
37. Estcourt M.J., McMichael A.J., Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol. Rev. 2004, 199:144-155.
38. Rice J., Ottensmeier C.H., Stevenson F.K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 2008, 8:108-120.
39. Kreijtz J.H.C.M., de Mustert G., van Baalen C.A., Fouchier R.A.M., Osterhous A.D.M.E., Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T lymphocyte populations directed to human influenza A virus. J. Virol. 2008, 82(11):5161-5166.
40. Nilges K., Hohn H., Pilch H., Neukirch C., Freitag K., Talbot P.J., Maeurer M.J. Human papillomavirus type 16E7 peptide-directed CD8+ T Cells from patients with cervical cancer are cross reactive with the coronavirus NS2 protein. J. Virol. 2003, 77(9):5464-5474.
41. McCarthy C., Youde S.J., Man S. Definition of an HPV 18/45 cross-reactive human T-cell epitope after DNA immunization of HLA-A2/KB transgenic mice. Int. J. Cancer 2006, 118:2514-2521.
42. Williams O.M., Hart K.W., Wang C.Y., Gelder C.M. Analysis of CD4+ T-Cell responses to human papillomavirus (HPV) Type 11 L1 in healthy adults reveal a high degree of responsiveness and cross-reactivity with other HPV types. J. Virol. 2002, 76(15):7418-7429.
43. Elben G.L., Velders M.P., Kast W.M. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv. Cancer Res. 2002, 113-148.